This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Mechanism of Action DosingDosing InformationDose AdjustmentsDrug Interactions Trial Design & EfficacyTrial DesignEfficacySafety Profile & Tolerability  Support & ResourcesPharmacy ResourcesHCP Experience VideosNICE Guidance

Prescribing Information for ▼PAXLOVID (nirmatrelvir / ritonavir) can be found here. Adverse event reporting information can be found at the bottom of the page.

Paxlovid has a Conditional Marketing Authorisation in the United Kingdom. A Conditional Marketing Authorisation means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information will be updated as necessary.

NICE Guidance (TA878) on treatments for patients with COVID-191View the NICE Guidance (TA878) here.1*
Paxlovid is recommended by NICE as a first line treatment for adult patients at increased risk of progression to severe COVID-191 

NICE has recommended treatments for patients who do not need supplemental oxygen and are at increased risk for progression to severe COVID-19, as defined by the Independent Advisory Group Report1,2

Remdesivir is also recommended as a treatment option in hospitals for adults and paediatric patients (weighing at least 40kg)6


The decision to treat and choice of treatment is based on the individual patient’s eligibility criteria, clinical circumstances and is ultimately at the discretion of the individual prescriber. Please refer to relevant SmPCs before making any prescribing decisions. 

 

Please click on the sections below to see the full list of risks factors for progression to severe COVID-19 (adapted from NICE TA878)1
Down's syndrome and other genetic disorders

All individuals with Down's syndrome or other chromosomal disorders known to affect immune competence.

Solid cancer
  • Metastatic or locally advanced inoperable cancer.
  • Lung cancer (at any stage).
  • People receiving any chemotherapy (including antibody-drug conjugates), PI3K inhibitors or radiotherapy within 12 months.
  • People who have had cancer resected within 3 months and who received no adjuvant chemotherapy or radiotherapy.
  • People who have had cancer resected within 3 to 12 months and receiving no adjuvant chemotherapy or radiotherapy are expected to be at less risk (and thus less priority) but still at increased risk compared with the non-cancer populations.
    • Haematological diseases and recipients of haematological stem cell transplant (HSCT)
  • Allogeneic HSCT recipients in the last 12 months or active graft versus host disease (GVHD) regardless of time from transplant (including HSCT for non-malignant diseases).
  • Autologous HSCT recipients in the last 12 months (including HSCT for non-malignant diseases).
  • Individuals with haematological malignancies who have received CAR-T cell therapy in the last 24 months, or until the lymphocyte count is within the normal range.
  • Individuals with haematological malignancies receiving systemic anticancer treatment (SACT) within the last 12 months, or radiotherapy in the last 12 months.
  • All people who do not fit the criteria above, and are diagnosed with:
  • Myeloma (excluding monoclonal gammopathy of undetermined significance [MGUS]).
  • AL amyloidosis.
  • Chronic B-cell lymphoproliferative disorders (chronic lymphocytic leukaemia, follicular lymphoma).
  • Myelodysplastic syndrome (MDS).
  • Chronic myelomonocytic leukaemia (CMML).
  • Myelofibrosis.
  • Any mature T-cell malignancy.
  • All people with sickle cell disease.
  • People with thalassaemia or rare inherited anaemia with any of the following:
  • Severe cardiac iron overload (T2 * less than 10 ms).
  • Severe to moderate iron overload (T2 * greater than or equal to 10 ms) plus an additional comorbidity of concern (for example, diabetes, chronic liver disease or severe hepatic iron load on MRI).
  • Individuals with non-malignant haematological disorders (for example, aplastic anaemia or paroxysmal nocturnal haemoglobinuria) receiving B-cell depleting systemic treatment (for example, anti-CD20, antithymocyte globulin [ATG] and alemtuzumab) within the last 12 months.
    • Renal disease
  • Renal transplant recipients (including those with failed transplants within the past 12 months), particularly those who have:
    • Received B-cell depleting therapy within the past 12 months (including alemtuzumab, rituximab [anti-CD20], ATG).
    • An additional substantial risk factor that would in isolation make them eligible for monoclonals or oral antivirals.
  • Non-transplant renal patients who have received a comparable level of immunosuppression.
  • Patients with chronic kidney disease (CKD) stage 4 or 5 (an estimated glomerular filtration rate [eGFR] less than 30 ml per min per 1.73 m2) without immunosuppression.

    • Paxlovid is contraindicated in patients with severe renal impairment.    Liver diseases
  • People with cirrhosis Child-Pugh (CP) class A, B and C, whether receiving immune suppressive therapy or not. Those with decompensated liver disease (CP B and C) are at greatest risk.
  • People with a liver transplant.
  • People with liver disease on immune suppressive therapy (including people with and without cirrhosis).

    • Paxlovid is contraindicated in patients with severe hepatic impairment.
    Solid organ transplant recipients
  • Solid Organ transplant recipients not in any of the above categories.
    • Immune-mediated inflammatory disorders
    IMIDs comprise diseases in which autoimmune or autoinflammation-based pathways are implicated in disease; for example, inflammatory arthritis, connective tissue diseases, inflammatory skin diseases, inflammatory gastrointestinal disease.
     
    • People who have received a B-cell depleting therapy (anti-CD20 drug, for example, rituximab, ocrelizumab, ofatumumab, obinutuzumab) in the last 12 months.
    • People who have been treated with cyclophosphamide (IV or oral) in the 6 months prior to positive PCR or relevant COVID test.
    • People who are on corticosteroids (equivalent to 10 mg or more per day of prednisolone) for at least the 28 days prior to positive PCR or relevant COVID test.
    • People who are on biologics or small molecule JAK inhibitors.
    • People who are on current treatment with mycophenolate mofetil, oral tacrolimus, azathioprine, mercaptopurine, or similar agents (for major organ involvement such as kidney, gastro-intestinal tract, liver, lung, brain), methotrexate (for interstitial lung disease or asthma only) and/or ciclosporin. No minimum dose threshold is suggested.
    • People who are on current treatment (or within the last 6 months) with S1P modulators (fingolimod, ponesimod or siponimod), or alemtuzumab or cladribine within the last 12 months.
    • People who exhibit at least one of: (a) uncontrolled or clinically active disease (that is, required recent increase in dose or initiation of new immunosuppressive drug or IM steroid injection or course of oral steroids within the 3 months prior to positive PCR or relevant COVID test); and/or (b) other high risk comorbidities (for example, body mass index [BMI] greater than 30, diabetes mellitus, hypertension, major organ involvement such as significant kidney, liver, nervous system or lung inflammation or significantly impaired renal, liver, nervous system and/or lung function).
    Respiratory
  • Asthma in people on oral corticosteroids (defined above in IMID section). Any asthma patient taking immunosuppressants for their asthma including but not exclusively methotrexate, ciclosporin. Frequent exacerbations requiring 4 or more courses of prednisolone per year, usually 40 mg per day for 5 days or more.
  • COPD on long term home non-invasive ventilation (NIV). Patients on long term oxygen therapy. People with moderate or severe disease (FEV1 less than or equal to 50% predicted) who have required 4 or more courses of prednisolone 30 mg for 5 days or greater in last 12 months.
  • Interstitial lung disease (ILD) – all patients with idiopathic pulmonary fibrosis.
  • Sub-types of ILD, for example, connective tissue disease related, sarcoidosis, hypersensitivity pneumonitis, NSIP (non-specific interstitial pneumonia) who have received a B-cell depleting therapy in last 12 months, or IV or oral cyclophosphamide in the 6 months prior to testing positive for COVID-19. Any ILD patient on current treatment with corticosteroids, mycophenolate mofetil, azathioprine, tacrolimus, cyclosporin or methotrexate. No minimum dose criteria.
  • Any people with any type of ILD who may not be on treatment due to intolerance but has severe disease with an FVC predicted less than 60%.
  • NIV and tracheostomy ventilated – all patients requiring this type of support regardless of the underlying disorder (which might include COPD, obesity hypoventilation syndrome, scoliosis, bronchiectasis, neurodisability and genetic muscular diseases [refer to neurology section]).
  • Lung cancer patients, refer to 'Solid cancer' section above.
  • Lung transplant patients (refer to solid organ transplant section).
  • Pulmonary hypertension (PH): groups 1 and 4 from PH classification.
    • Immune deficiencies
  • Common variable immunodeficiency (CVID).
  • Undefined primary antibody deficiency on immunoglobulin (or eligible for Ig).
  • Hyper-IgM syndromes.
  • Good's syndrome (thymoma plus B-cell deficiency).
  • Severe combined immunodeficiency (SCID).
  • Autoimmune polyglandular syndromes or autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED syndrome).
  • Primary immunodeficiency associated with impaired type 1 interferon signalling.
  • X-linked agammaglobulinaemia (and other primary agammaglobulinaemias).
  • Any person with secondary immunodeficiency receiving, or eligible for, immunoglobulin replacement therapy.
    • HIV/AIDS
  • People with high levels of immune suppression, have uncontrolled or untreated HIV (high viral load) or present acutely with an AIDS defining diagnosis.
  • People on treatment for HIV with CD4 less than 350 cells per mm3 and stable on HIV treatment or CD4 greater than 350 cells per mm3 and additional risk factors (for example, age, diabetes, obesity, cardiovascular, liver or renal disease, homeless, alcoholic dependency).
    • Neurological disorders
  • Conditions associated with neuromuscular respiratory failure requiring chronic ventilatory support:
  • Motor neurone disease.
  • Duchenne muscular dystrophy.
  • Conditions that require use of specific immunotherapies:
  • Multiple sclerosis (MS).
  • Myasthenia gravis (MG).
  • Other immune-mediated disorders.
  • Dementia, neurodegenerative and neuroimmune disorders when associated with severe frailty (for example, levels 7 or 8 on Clinical Frailty Scale, as part of a personalised care plan):
  • Alzheimer's disease, vascular disease, Lewy body disease, or frontotemporal atrophy
  • Parkinson's disease.
  • Huntington's disease.
  • Progressive supranuclear palsy and multiple system atrophy.
  • Motor neurone disease.
  • Multiple sclerosis and other immune-mediated neurological disorders.
    • Join us! 

    Set up a PfizerPro account to access further materials and resources, and receive communication about medicines and vaccines promoted by Pfizer. 

     Join now
    Dosing Dosing Information Guide

    Learn about PAXLOVID dosing, potential drug interactions, and how to prescribe.

     Download Loading    GB

    Educational ResourcesExplore downloadable materials to further support both you and your patients. 

     Explore more     How PAXLOVID WorksLearn about how PAXLOVID inhibits replication by preventing proteolysis from occurring. Find out more

    Explore more videos

    Watch short educational key-opinion-leader (KOL) videos from Healthcare Professionals on their experience in managing patients at risk of severe COVID-19.

    HCP Experience Videos
         *Links to a third-party-website (outside of Pfizer). Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. Pfizer accepts no responsibility for the content or services of the linked site.
     
    References:
    1.©NICE [2025] TA878. Available at: https://www.nice.org.uk/guidance/ta878* (Accessed September 2025). All rights reserved. Subject to Notice of rights.
    NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication 
    2.GOV.UK. Defining the highest-risk clinical subgroups upon community infection with SARS-CoV-2 when considering the use of neutralising monoclonal antibodies (nMABs) and antiviral drugs: independent advisory group report. Available at: https://www.gov.uk/government/publications/higher-risk-patients-eligible-for-covid-19-treatments-independent-advisory-group-report-march-2023* (Accessed September 2025).
    3. PAXLOVID® Summary of Product Characteristics.
    4. Xevudy (sotrovimab) Summary of Product Characteristics.
    5. Lagevrio (molnupiravir) Summary of Product Characteristics.
    6. ©NICE [2025] TA971. Available at: https://www.nice.org.uk/guidance/ta971* (Accessed September 2025). All rights reserved. Subject to notice of rights.
    NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
    PP-C1D-GBR-0732 September 2025

    Adverse Events
     

    Adverse Events should be reported. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search 

    for MHRA Yellow Card in Google Play or Apple App Store

     

    Adverse events should also be reported to Pfizer Medical Information on 01304 616161

    PfizerPro Account

    To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

    Sign In or RegisterAccountSign Out

    This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

     

    This website is brought to you by Pfizer Limited, a company registered in England 

    and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

     

    Copyright © 2025 Pfizer Limited. All rights reserved.

     

    VAT registration number GB201048427

    PP-C1D-GBR-0535. January 2025
    For UK Healthcare Professionals*

    These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

    I confirm that I am a healthcare professional* resident in the United Kingdom.

    If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

    *The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

    PP-UNP-GBR-7812. January 2024.

    YesNo
    You are now leaving PfizerPro​​​​​
    ​
    You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

    Pfizer accepts no responsibility for the content or services of the linked site.

    PP-UNP-GBR-12070. April 2025​​​​​​​
    ​​​​​​​
    You are now leaving PfizerPro

    ​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

    Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer's medicines or business which it has provided or reviewed.

    PP-UNP-GBR-12107. April 2025
    ​​​​​​​